I Reinders1, R A Murphy2, X Song3, M Visser4, M F Cotch5, T F Lang6, M E Garcia2, L J Launer2, K Siggeirsdottir7, G Eiriksdottir7, P V Jonsson8, V Gudnason9, T B Harris2, I A Brouwer10. 1. 1] Laboratory of Epidemiology and Population Sciences, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA [2] Department of Health Sciences and the EMGO Institute for Health and Care Research, VU UniversityAmsterdam, The Netherlands. 2. Laboratory of Epidemiology and Population Sciences, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA. 3. Biomarker Laboratory, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 4. 1] Department of Health Sciences and the EMGO Institute for Health and Care Research, VU UniversityAmsterdam, The Netherlands [2] Department of Nutrition and Dietetics, Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands. 5. Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, MD, USA. 6. Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA. 7. Icelandic Heart Association Research Institute, Kopavogur, Iceland. 8. Department of Geriatrics, Landspitali National University Hospital and Faculty of Medicine, University of Iceland, Reykjavik, Iceland. 9. 1] Icelandic Heart Association Research Institute, Kopavogur, Iceland [2] Faculty of Medicine, University of Iceland, Reykjavik, Iceland. 10. Department of Health Sciences and the EMGO Institute for Health and Care Research, VU UniversityAmsterdam, The Netherlands.
Abstract
BACKGROUND/ OBJECTIVES: Low intake of long chain polyunsaturated fatty acids (PUFAs) are associated with physical disability; however, prospective studies of circulating PUFAs are scarce. We examined associations between plasma phospholipid n-3 and n-6 PUFAs with risk of incident mobility disability and gait speed decline. SUBJECTS/ METHODS: Data are from a subgroup of the Age, Gene/Environment Susceptibility-Reykjavik Study, a population-based study of risk factors for disease and disability in old age. In this subgroup (n = 556, mean age 75.1 ± 5.0 years, 47.5% men), plasma phospholipid PUFAs were assessed at baseline using gas chromatography. Mobility disability and usual gait speed were assessed at baseline and after 5.2 ± 0.2 years. Mobility disability was defined as the following: having much difficulty, or being unable to walk 500 m or climb up 10 steps; decline in gait speed was defined as change ⩾ 0.10 m/s. Logistic regression analyses were performed to determine associations between sex-specific s.d. increments in PUFAs with risk of incident mobility disability and gait speed decline. Odds ratios (95% confidence intervals) adjusted for demographics, follow-up time, risk factors and serum vitamin D were reported. RESULTS: In women, but not men, every s.d. increment increase of total n-3 PUFAs and docosahexaenoic acid (DHA) was associated with lower mobility disability risk, odds ratio 0.48 (0.25; 0.93) and odds ratio 0.45 (0.24; 0.83), respectively. There was no association between n-6 PUFAs and the risk of incident mobility disability or gait speed decline. CONCLUSIONS: Higher concentrations of n-3 PUFAs and, particularly, DHA may protect women from impaired mobility but does not appear to have such an effect in men.
BACKGROUND/ OBJECTIVES: Low intake of long chain polyunsaturated fatty acids (PUFAs) are associated with physical disability; however, prospective studies of circulating PUFAs are scarce. We examined associations between plasma phospholipid n-3 and n-6 PUFAs with risk of incident mobility disability and gait speed decline. SUBJECTS/ METHODS: Data are from a subgroup of the Age, Gene/Environment Susceptibility-Reykjavik Study, a population-based study of risk factors for disease and disability in old age. In this subgroup (n = 556, mean age 75.1 ± 5.0 years, 47.5% men), plasma phospholipidPUFAs were assessed at baseline using gas chromatography. Mobility disability and usual gait speed were assessed at baseline and after 5.2 ± 0.2 years. Mobility disability was defined as the following: having much difficulty, or being unable to walk 500 m or climb up 10 steps; decline in gait speed was defined as change ⩾ 0.10 m/s. Logistic regression analyses were performed to determine associations between sex-specific s.d. increments in PUFAs with risk of incident mobility disability and gait speed decline. Odds ratios (95% confidence intervals) adjusted for demographics, follow-up time, risk factors and serum vitamin D were reported. RESULTS: In women, but not men, every s.d. increment increase of total n-3 PUFAs and docosahexaenoic acid (DHA) was associated with lower mobility disability risk, odds ratio 0.48 (0.25; 0.93) and odds ratio 0.45 (0.24; 0.83), respectively. There was no association between n-6 PUFAs and the risk of incident mobility disability or gait speed decline. CONCLUSIONS: Higher concentrations of n-3 PUFAs and, particularly, DHA may protect women from impaired mobility but does not appear to have such an effect in men.
Authors: Sian M Robinson; Karen A Jameson; Sue F Batelaan; Helen J Martin; Holly E Syddall; Elaine M Dennison; Cyrus Cooper; Avan Aihie Sayer Journal: J Am Geriatr Soc Date: 2007-11-15 Impact factor: 5.562
Authors: Erik B Schelbert; Jie J Cao; Sigurdur Sigurdsson; Thor Aspelund; Peter Kellman; Anthony H Aletras; Christopher K Dyke; Gudmundur Thorgeirsson; Gudny Eiriksdottir; Lenore J Launer; Vilmundur Gudnason; Tamara B Harris; Andrew E Arai Journal: JAMA Date: 2012-09-05 Impact factor: 56.272
Authors: Hsu-Ko Kuo; Richard N Jones; William P Milberg; Sharon Tennstedt; Laura Talbot; John N Morris; Lewis A Lipsitz Journal: J Am Geriatr Soc Date: 2005-07 Impact factor: 5.562
Authors: Anoop Balachandran; David M Gundermann; Michael P Walkup; Abby C King; Walter T Ambrosius; Stephen B Kritchevsky; Marco Pahor; Anne B Newman; Todd M Manini Journal: Med Sci Sports Exerc Date: 2020-04
Authors: S M Robinson; J Y Reginster; R Rizzoli; S C Shaw; J A Kanis; I Bautmans; H Bischoff-Ferrari; O Bruyère; M Cesari; B Dawson-Hughes; R A Fielding; J M Kaufman; F Landi; V Malafarina; Y Rolland; L J van Loon; B Vellas; M Visser; C Cooper Journal: Clin Nutr Date: 2017-08-24 Impact factor: 7.324
Authors: C M Imai; T I Halldorsson; T Aspelund; G Eiriksdottir; L J Launer; I Thorsdottir; T B Harris; V Gudnason; I A Brouwer; I Gunnarsdottir Journal: J Nutr Health Aging Date: 2018 Impact factor: 5.285